SMR Stemless Reverse vs SMR Reverse Shoulder System
Recruiting · Not applicable · NCT04697004
Conditions: Arthroplasty, Replacement
At a glance
- Research payments reported, 2025
- $5,864
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 200
About the trial
- Sponsor
- Limacorporate S.p.a (with NAMSA)
- Tested
- Investigational Arm: SMR Stemless Reverse (device), Control Arm: SMR Reverse Shoulder System (device)
- Dates
- Started 2021-04-01; completion 2028-12-30
- Results posted
- Not yet
The SMR Stemless Reverse is intended for total, primary shoulder joint replacement by reducing pain and restoring shoulder articular mobility function. This is a prospective, multi-center, randomized, controlled trial to demonstrate non-inferiority of the SMR Stemless Reverse to the SMR Reverse Shoulder System. Patients with joint dysfunction who continue to experience significant symptoms despite an appropriate course of non-operative management are eligible. Patients will be considered enrolled into the study when an ICF has been signed, all inclusion criteria are met and no exclusion criteria are present including intraoperative exclusion criteria, and the patient is randomized into ei…
From ClinicalTrials.gov, last updated 2026-10-28. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Encore Medical, LP reported $5,864 in research payments for this study in 2025 (1 payments).
Products named: Djo Surgical
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- More Foundation $5,864
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.